Search
Actinium Pharmaceuticals Inc
ATNMAdd to Watchlist
0.867USD
+0.012+1.42%
Close 07-28 16:00（ET）Quotes delayed by 15 min
27.19MMarket Cap
LossP/E TTM
More Details of Actinium Pharmaceuticals Inc Company
Actinium Pharmaceuticals, Inc. specializes in the development of targeted radiotherapies. The Company is advancing its lead product candidate Actimab-A, a CD33 targeting therapeutic, as potential backbone therapy in acute myeloid leukemia (AML) and other myeloid malignancies leveraging the mutation agnostic alpha-emitter radioisotope payload Actinium-225 (Ac-225). The Company is engaged with the National Cancer Institute (NCI) under the Cooperative Research and Development Agreement (CRADA) for development of Actimab-A in AML and other myeloid malignancies. ATNM-400 is the Company's novel non-PSMA targeting Ac-225 radiotherapy for prostate cancer. Iomab-ACT, its conditioning candidate, is being developed to improve patient access and outcomes for potentially curative cell and gene therapies. Its Iomab-B program is an induction and conditioning agent prior to bone marrow transplant in patients with r/r AML, which it is seeking a potential strategic partner for the United States.
Actinium Pharmaceuticals Inc Info
Ticker SymbolATNM
Company nameActinium Pharmaceuticals Inc
IPO dateMar 26, 2014
CEOSeth (Sandesh)
Number of employees37
Security typeOrdinary Share
Fiscal year-endMar 26
Address100 Park Ave., 23Rd Floor
CityNEW YORK
Stock exchangeNASDAQ OMX – NASDAQ Basic Amex
CountryUnited States of America
Postal code10017
Phone16466773870
Websitehttps://www.actiniumpharma.com/
Ticker SymbolATNM
IPO dateMar 26, 2014
CEOSeth (Sandesh)
Company Executives of Actinium Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Sandesh (Andes) Seth
Mr. Sandesh (Andes) Seth
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
184.48K
--
Dr. Ajit S. Shetty, Ph.D.
Dr. Ajit S. Shetty, Ph.D.
Independent Director
Independent Director
757.00
--
Mr. Richard I. Steinhart
Mr. Richard I. Steinhart
Independent Director
Independent Director
316.00
--
Dr. C. David Nicholson, Ph.D.
Dr. C. David Nicholson, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Steve O'Loughlin
Mr. Steve O'Loughlin
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
--
--
Dr. Jeffrey W. Chell, M.D.
Dr. Jeffrey W. Chell, M.D.
Independent Director
Independent Director
--
--
Dr. June S. Almenoff, M.D., Ph.D.
Dr. June S. Almenoff, M.D., Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Sandesh (Andes) Seth
Mr. Sandesh (Andes) Seth
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
184.48K
--
Dr. Ajit S. Shetty, Ph.D.
Dr. Ajit S. Shetty, Ph.D.
Independent Director
Independent Director
757.00
--
Mr. Richard I. Steinhart
Mr. Richard I. Steinhart
Independent Director
Independent Director
316.00
--
Dr. C. David Nicholson, Ph.D.
Dr. C. David Nicholson, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Steve O'Loughlin
Mr. Steve O'Loughlin
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
--
--
Dr. Jeffrey W. Chell, M.D.
Dr. Jeffrey W. Chell, M.D.
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Actinium Pharmaceuticals Inc?
The top five shareholders of Actinium Pharmaceuticals Inc are: Mr. Sandesh (Andes) Seth
How many institutions hold shares of Actinium Pharmaceuticals Inc (ATNM)?
As of 2026Q1, 185 institutions hold shares of Actinium Pharmaceuticals Inc, with a combined market value of approximately 6.47M, accounting for 20.62% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -2661354.00.